Eli Lilly signed a new China discovery-stage pact with InnoCare Pharma, extending its run of large partnerships to source oncology and other drug innovation from China. The agreement spans up to five undisclosed targets, with Lilly gaining rights to develop and commercialize resulting candidates. The deal structure includes $100 million in upfront and near-term payments and up to $3.25 billion in development and commercial milestones, plus royalties. The partnership follows other recent Lilly China alliances, reinforcing the company’s strategy to diversify early discovery inputs while building options across multiple therapeutic areas. Analysts and industry observers have treated these deals as a way for multinational drugmakers to accelerate candidate flow, particularly in oncology, where target landscapes and biomarker programs evolve rapidly. InnoCare’s technical focus aligns with Lilly’s stated desire to expand its China-sourced discovery pipeline while managing timing and development risk through milestone-based funding.